InflaRx N.V. (IFRX): Price and Financial Metrics

InflaRx N.V. (IFRX): $1.54

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

F

Add IFRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#305 of 363

in industry

IFRX Price/Volume Stats

Current price $1.54 52-week high $7.25
Prev. close $1.54 52-week low $1.14
Day low $1.52 Volume 190,100
Day high $1.60 Avg. volume 246,123
50-day MA $1.61 Dividend yield N/A
200-day MA $2.55 Market Cap 68.84M

IFRX Stock Price Chart Interactive Chart >


InflaRx N.V. (IFRX) Company Bio


Fireman B.V. (InflaRx) operates as a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies drugs for the treatment of inflammatory diseases. The company is based in Jena, Germany.


IFRX Latest News Stream


Event/Time News Detail
Loading, please wait...

IFRX Latest Social Stream


Loading social stream, please wait...

View Full IFRX Social Stream

Latest IFRX News From Around the Web

Below are the latest news stories about INFLARX NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.

Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing

InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | December 1, 2023

After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)

InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | November 28, 2023

InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | November 6, 2023

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin disease characterized by painful ulcers that can rapidly progress JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the first patient has been dosed in its P

Yahoo | November 6, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today!

William White on InvestorPlace | November 3, 2023

Read More 'IFRX' Stories Here

IFRX Price Returns

1-mo -6.67%
3-mo -5.52%
6-mo -48.32%
1-year -13.48%
3-year -57.46%
5-year -95.92%
YTD -5.52%
2023 -47.42%
2022 -34.87%
2021 -5.37%
2020 27.02%
2019 -89.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!